A. Blauvelt, “Bimekizumab provides rapid and sustained improvements in scalp and nail outcomes in patients with moderate to severe plaque psoriasis: 60 week results from a randomized, double blinded, Phase 2b extension study”, J of Skin, vol. 3, p. S34, Nov. 2019.